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Birth outcomes such as gestational age, or environmental exposures like mercury, 
serve either as one of the strongest predictors for neonatal, adolescent, and adult 
morbidity and mortality or associated with common diseases such as cancer, 
cardiovascular disease, and neurological disorders through unknown mechanisms. 
Identification of genomic loci undergoing epigenetic changes, specifically DNA 
methylation, would increase our understanding of these unknown mechanisms. To 
address this, we performed CHARM 2.0, a genome-wide array-based analysis of DNA 
methylation, in 141 newborns collected in Baltimore, Maryland using bump-hunting 
based novel statistical methodology to identify genomic regions associated with 
gestational age. Through this analysis, we identified three DMRs at genome-wide 
significance levels associated with gestational age near three genes (NFIX, RAPGEF2 
and MSRB3) and one DMR commonly associated with total and methyl mercury 
exposure (TCEANC2). All of the three regions associated with gestational age were 
validated, and the region associated with both mercury exposure types were replicated by 
bisulphite pyrosequencing. Of the genes near or containing the DMRs, RAPGEF2 and 
TCEANC2 gene showed an inverse correlation between DNA methylation level and its 
expression level. For all of the gestational age DMRs, the DNA methylation levels at 
these regions appear similar or more extreme than those of the latest gestational ages in a 
heterogeneous population of adults. Together, the existence of gestational age DMRs 
suggests that epigenetic changes can occur not only during embryogenesis, but also 
during later stages of gestation. Also, The existence of mercury DMRs raise the 
 iii 
possibility that environmental exposures, particularly heavy metals during pregnancy, 
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Epigenetics is defined as the study of heritable marks other than the primary DNA 
sequence itself. Although DNA methylation is the only epigenetic mark proven to meet 
the traditional definition as a heritable mark through cell division, epigenetics now cover 
far more marks due to the complex nature and interactions between different marks 
including DNA methylation. Epigenetic marks now cover DNA cytosine modifications 
(hydroxylation, formylation and carboxylation), histone post-translational modifications 
(methylation, acetylation, phosphorylation, ubiquitination, sumonylation, crotonylation), 
and histone variants (H3.3, H2AZ, macroH2A, γH2AX). Together, these marks 
determine the chromatin environment inside nucleus such as nucleosome occupancy, 
high order chromatin structures like Large Organized Chromatin K modifications 
(LOCKs) (Wen et al., 2009), hypomethylated blocks (Hansen et al., 2011), Partially 
Methylated Domains (PMDs) (Lister et al., 2009) and Lamin Associated Domains (LADs) 
(Guelen et al., 2008). Although not an epigenetic mark itself, non-coding RNAs such as 
long intergenic non coding RNAs (lincRNAs) and enhancer RNAs (eRNAs) in 
mammalian system are included due to their role of mediating changes in epigenetic 
marks and chromatin structure (Mousavi et al., 2013; Tsai et al., 2010). Collectively, 
epigenetic marks, chromatin environment, and non-coding RNAs are important in both 
establishment of cellular identity and in disease context, such as cancer or common 
diseases.  
One of the epigenetic marks is DNA methylation, which occurs at the fifth carbon 
position of the DNA cytosine nucleotide in vertebrates.  Generally, DNA methylation 
occurs in the context of CpG dinucleotides, but non-CpG methylation has also been 




Methylation of DNA is catalyzed by DNA methyltransferases (DNMTs) by transferring 
methyl group from S-Adenosyl Methionine (SAM) to cytosine. Of the DNMTs, DNMT1 
serves as a maintenance methyltrasnferase by methylatng hemimethylated DNA during 
the DNA replication process. DNMT3A and B are de novo methyltransferases. 
Demethylation of DNA can occur passively by not replicating methylation patterns to 
daughter strand, or actively through combination of base excision repair (BER), 
nucleotide excision repair (NER) pathway and Ten Eleven Translocation (TET) enzymes 
(Wu and Zhang, 2010). Specifically, TET enzymes catalyze the oxidation of 5-
methylcytosine to 5-hydroxymethylcytosine (Tahiliani et al., 2009), and further catalyze 
to 5-formylcytosine and 5-carboxycytosine, and finally excised by Thymine-DNA 
Glycosylase (TDG) (He et al., 2011; Ito et al., 2011). These demethylation intermediate 
marks were observed in many tissue types, but most abundantly in early embryos, 
embryonic stem cells, primordial germ cells, purkinje neurons, and hippocampal dental 
gyrus (Guo et al., 2011; Kriaucionis and Heintz, 2009).   
One of the recent technological developments relevant for DNA methylation 
research is the establishment of genome-scale DNA methylation assay, either utilizing 
array-based or sequencing based systems. One of the array based genome-scale 
methylation technology used in this thesis study and other published studies is called 
Comprehensive High-throughput Array-based Relative Methylation (CHARM) assay, 
which utilized McrBC, a methyl-sensitive restriction enzyme. The original CHARM 
array design (custom designed NimbleGen HD2) interrogates 4.6 million CpGs across the 
genome, and covers almost all of the CpG islands, promoters, and non-repetitive lower 




array system, investigators not only found methylation signature patterns across different 
cell and tissue types but also identified new discoveries which could not be found from 
using CpG-island focused arrays, including the finding that most methylation changes 
observed between different tissues (brain, liver and spleen), colon cancer, hematopoiesis 
and iPSC system are not at CpG islands but at CpG island shores, defined as sequences 
up to 2kb distant from CpG islands (Doi et al., 2009; Irizarry et al., 2009; Ji et al., 2010). 
Other array based genome-scale assays such as Infinium HumanMethylation450 
BeadChip assay are also widely used in various DNA methylation research areas. One of 
the sequencing based DNA methylation assays called Whole Genome Bisulfite 
Sequencing is by far the most comprehensive genome-scale DNA methylation assay. 
This assay is based on treating bisulfite on genomic DNA, which converts unmethylated 
cytosine to uracil, whereas methylated cytosine remains unconverted (Krueger et al., 
2012). Thus, bisulfite treatment creates sequence differences based on cytosine 
methylation status of DNA. After shearing genomic DNA, bisulfite treatment, the 
prepared sequence library is subjected to next generation sequencer. This approach 
enabled us to create genome-wide, single-base resolution DNA methylation map on 
various organisms including Arabidopsis thaliana (Cokus et al., 2008; Lister et al., 2008), 
and in human system (Lister et al., 2013; Lister et al., 2009; Lister et al., 2011). In 
addition, this technology directed us to new discoveries such as identification of non-
CpG methylation and large methylation structures (PMDs and blocks), which blocks 
found to display stochastic variation in several types of tumor tissues with large-scale 




One of the rising epigenetic research fields along with the described technological 
advancements in genome-scale DNA methylation assay is epigenetic epidemiology, or 
Epigenome-Wide Association Studies (EWAS). These population-level genome scale 
studies are important since it’s possible that epigenetic marks influence disease 
phenotypes by affecting the expression of target genes independent of or interacting with 
any sequence variation within or nearby the gene and the environmental factors 
(Bjornsson et al., 2004). EWAS started to replace traditional approaches to conduct 
epigenetic assays targeting selected candidate genes previously known to be involved in 
diseases, and they hold great promise for systematically dissecting out the role of 
epigenetic variation in health and disease (Michels et al., 2013). One of the several 
challenges for EWAS is to establish statistical methodology to properly deal with large-
scale epigenetic data combined with epidemiological database. Although recent EWAS 
adopted GWAS-like approach to identify association between the phenotype of interest 
and DNA methylation at individual CpG level, more advanced strategies to analyze DNA 
methylation data by identification of Differentially Methylated Regions (DMRs) can be 
more productive (Bock, 2012). Recent work suggested novel statistical analysis tool 
called bump-hunting in order to identify DMRs based on techniques that borrows 
statistical power from adjacent CpGs to produce estimates that are substantially more 
precise than methods focusing on individual CpGs for EWAS (Jaffe et al., 2012b). 
In the subsequent chapters, two perinatal EWAS to identify DNA methylation 
differences associated with birth outcomes and environmental exposure, particularly 
gestational age and mercury exposure levels are described. Experimentally, CHARM 2.0, 




which further described in Laboratory Analyses part in Materials and Methods chapter. 
For biostatistical analysis, bump-hunting algorithm was used to identify DMRs 
associated with our variables of interest, which further described in Statistical Analyses 
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Chapter 2: Introduction 
 
 
Part of this chapter is reproduced from published article in International Journal of 











Childhood disorders such as autism spectrum disorders (ASD) present lifetime 
challenges for children and their families with huge impact on public health. For example, 
ASDs may affect as many as 1 in 150 children with showing symptoms such as absent or 
delayed non-verbal communication, impaired social interactions, and rote or repetitive 
behaviors (Rice et al., 2007). The identification of causes and mechanisms for the 
progression of such disorders would have profound impact on the diagnosis, prevention, 
and possible treatment of these public health problems. The causes of childhood disorders 
could be environment (either in utero or post-birth), inherent genetics and epigenetic 
signatures such as DNA methylation. Thus, integration of the environmental exposure 
status, birth outcomes, genetics, and epigenetics of neonates would be the most 
comprehensive way to find the ultimate cause for the disorders.  
Gestational age is the age of fetus in utero, and serves as one of the birth 
outcomes. Gestational age is the most important indicator of perinatal mortality in 
developed countries (Goldenberg et al., 2008), and also contributes to childhood and 
adult morbidity and mortality (Crump et al., 2011; Saigal and Doyle, 2008; Swamy et al., 
2008).  In 2005, approximately 13% of infants in the USA were born pre-term (<37 
weeks), a rise from <10% in 1990 (Martin et al., 2007). The mechanism by which pre-
term birth (PTB) increases morbidity and mortality is largely unknown. Recognition of 
specific genes that are still undergoing regulatory change prior to birth would not only 
increase our understanding of the developmental changes that are occurring during late 
pregnancy, but also it would aid in identifying genetic, epigenetic and environmental 
factors that could lead to PTB. The risks of negative public health consequences of PTB 




2010). Identification of epigenetic factors has the potential to prevent or ameliorate these 
adverse impacts. 
Mercury, one of the toxic heavy metals, act as an environmental factor causing 
severe health consequences with symptoms such as sensory disturbance, visual field 
constriction, ataxia and deafness (Edwards, 1865).  Of the several forms of inorganic and 
organic mercury, the major form of the mercury exposure in human is through methyl 
mercury (WHO, 2010). The known major sources of methyl mercury exposure are diet, 
particularly large fish and seafood, and socioeconomic status (Golding et al., 2013). The 
toxicity of high level methyl mercury exposure has been shown by multiple historical 
episodes such as Minamata disease and Iraq poison grain syndrome, affecting more on 
fetus due to in utero exposure with similar health consequences comparing to adults 
(Bakir et al., 1973; Social Scientific Study Group on Minamata Disease, 1999).  
Furthermore, a case from Swedish family with infants suffering from mental retardation 
and severe deficient in motor development without any effect on the mother emphasized 
the fetal effect of methyl mercury exposure in utero (Engleson and Herner, 1952). Not 
only high-level methyl mercury exposures show these fetal disorders, low-level methyl 
mercury exposure can also affect fetus in utero, showing association with brain function 
deficits (Grandjean et al., 1997). Identification of epigenetic factors associated with the 
exposure levels would reveal potential mechanisms inducing the adverse health outcomes 
and possibly prevent or ameliorate them. 
From the point of view of a developmental change that is associated with health 
risk and environmental mediators, epigenetic changes in the fetus are potentially 




within an individual across developmental stages. A significant challenge in 
understanding the role of epigenetic changes in epidemiology is integrating novel 
molecular, epidemiological and biostatistical tools at a genome-scale level. Unlike 
classical genome sequence analyses, the methods and study designs for whole genome 
epigenetic epidemiology are not yet well established. The approach we have taken here is 
to design a genome-scale epidemiological analysis a priori from this joint conceptual 
perspective. We focused on DNA methylation because it is a key primary epigenetic 
process, with a well-established mechanism for propagating non-sequence-based 
information during cell division. The DNA methylation analysis presented here can serve 
as a paradigm for other epidemiological studies intending to characterize epigenetic 
profiles in specimen repositories, in which DNA methylation but not other epigenetic 
marks (e.g. histone modifications) are preserved. We have applied a significant 
technological extension of our previously described comprehensive high-throughput 
array-based relative methylation (CHARM) approach (Irizarry et al., 2008) that can now 
detect 5.2 million cytosine–guanine dinucleotide (CpG) sites which can be subject to 
DNA methylation. We also formally define an epigenetic variable, termed differentially 
methylated region (DMR), which we have used previously, but now have advanced its 
genome-wide detection to include novel statistical strategies to improve signal to noise 
detection, as well as the concept of regional methylation detection (Jaffe et al., 2012b).  
While one would expect large-scale epigenetic changes to occur between early 
embryogenesis and the end of gestation, at present nothing is known about epigenetic 
changes in the fetus that occur relatively late in pregnancy, covering intervals relevant to 




outcomes. Epigenetic changes in placental samples across gestation have been observed, 
implying the importance of such modifications for support of a growing fetus (Novakovic 
et al., 2011), but genome-scale and site-specific methylation data on the fetus itself, and 
with respect to the late gestational ages associated with most births, have not yet been 
reported before our publication. Also, no genome-scale study has been yet performed to 
discover the association between metal exposures, particularly mercury. The integration 
of the findings from these two genome-scale studies and other studies would enhance our 
knowledge of how epigenetics would be involved in the birth outcomes and exposures, 
and direct possible changes in the medical policy for pregnant women. For these reasons, 
we performed a genome-scale comprehensive analysis of DNA methylation on 141 
newborns to identify regions of the genome with DNA methylation levels correlated to 
gestational age at birth and mercury exposure. We then validated and replicated these 
microarray results via bisulphite sequencing. For gestational age DMRs, we further 
characterized the relationship between developmental age and DNA methylation at the 
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1. Study Samples 
 
 
Cord blood clot samples were obtained from the Baltimore Tracking Health 
Related to Environmental Exposures [THREE] Study (Apelberg et al., 2007). THREE is 
a cross-sectional sample of newborns born at the Johns Hopkins Hospital in Baltimore, 
MD, between November 2004 and March 2005. Of the 603 children delivered during that 
time window, 300 were eligible (24 twin births removed, 291 did not have any or ample 
cord blood available). Of these, 187 contributed a cord blood clot from which DNA could 
be isolated for the epigenetic project. Clots were saved during the second half of the data 
collection period.  
Cord blood buffy coat samples and maternal first and third trimester blood buffy 
coat samples were obtained from the Vanguard Study, which is a pilot study of National 
Children's Study [NCS]. Briefly, a total of 384 (147 maternal first and third trimester 
period peripheral blood, 90 cord blood) buffy coat samples were collected from seven 
different locations across U.S (Duplin County, NC; Queens County, NY; Orange County, 
CA; Waukesha County, WI; Salt Lake City, UT; Montgomery County, PA; composite 
location of four adjacent counties in South Dakota and Minnesota). Of those, 147 
maternal first trimester period peripheral blood buffy coat samples and 90 cord blood 
buffy coat samples were subjected to DNA isolation and Infinium HumanMethylation450 
assay (Illumina). 85 cord blood buffy coat samples were subjected to bisulfite 
pyrosequencing assay. 
For both of the birth cohorts, similar distribution for total and methyl mercury 




index and n-3 fatty acid level were shown between the population subjected to this study 
and the rest of the study population. Study personnel abstracted data from maternal and 
infant medical records and study clinicians reviewed a 10% random sample for accuracy; 
gestational age was taken as the best obstetrical estimate. Information on potential 
confounders was based on clinical records. Women who reported smoking during 
pregnancy or had an umbilical cord serum cotinine measurement > 10 ng/ml were 
considered active smokers; the remainder were considered passive smokers or non-
smokers (not reporting smoking and cotinine <1 ng/ml) (Bernert et al., 1997). Copper 
(previously found to be associated with gestational age in this population) and selenium 
were measured in umbilical cord serum using inductively coupled plasma dynamic 
reaction cell mass spectrometry (ICP–DRC– MS) (CDC, 2008) at Centers for Disease 
Control and Prevention (CDC) laboratories, with 4 mg/dl as the limit of detection. Total 
and methyl mercury and lead levels were measured by high performance liquid 
chromatography linked with inductively coupled plasma mass spectrometry (HPLC-ICP-
MS). For analysis of n-3 fatty acid levels, cord serum samples were transferred to United 
States National Institute of Alcohol Abuse and Alcoholism (NIAAA) via automated fast 
gas chromatography (Wells et al., 2011).  The THREE study was reviewed and approved 
by the Johns Hopkins School of Medicine Institutional Review Board, and the NCS 
Vanguard Study samples were collected under the authority of the NIH and study center 
IRBs. 
For comparison of newborn methylation results with adult samples, CHARM 2.0 
data were available on 156 adult samples obtained as unrelated controls for a 




2007; Gur et al., 2007). This sample was 40% male and had a broad age range of between 
16 and 89 years (interquartile range 31–55 years). DNA was obtained from the Rutgers 
University Cell & DNA Repository (RUCDR). DNA had been isolated from whole blood 
using Qiagen Autopure LS and pellets were hydrated in 1% Tris-EDTA (TE) buffer. 
Sample concentration and integrity were verified locally using NanoDrop and gel 
electrophoresis. DNA methylation was measured using the CHARM 2.0 assay. 
 
2. Laboratory Analyses  
 
a. CHARM DNA methylation 
 
DNA was isolated from cord blood clot samples using the DNeasy
®
 Blood & 
Tissue kit (Qiagen), following the manufacturer’s instructions. From the 187 fetal cord 
blood clot samples available, 167 (89.3%) yielded enough DNA for methylation array 
analysis. DNA methylation was measured via the CHARM 2.0 assay, a customized 
microarray method extended from our previous CHARM procedure, a genomescale 
microarray technique for DNA methylation that identifies differential DNA methylation 
without assumptions regarding where such changes would be, interrogating all CpG 
islands, as well as CpG island ‘shores’ (Irizarry et al., 2009). CHARM 2.0 now includes 
2.1 million probes, which cover 5.2 million CpGs arranged into probe groups (where 
consecutive probes are within 300 bp of each other) that tile regions of at least moderate 
CpG density. It includes all annotated and non-annotated promoters and microRNA sites 




specifications are freely available on our website (rafalab.jhu.edu). For the CHARM 2.0 
assay, 5 mg of purified genomic DNA was sheared, digested, purified, amplified, labeled 
as described (Ladd-Acosta et al., 2010), but hybridized onto our new CHARM 2.0 array. 
We dropped 26 arrays with <80% of their probes above background intensities, resulting 
in 141 samples for DNA methylation analysis. We then filtered probes where signal was 
below background in <25% of arrays (542,055) and removed sex chromosomes (39,454) 
to improve the batch correction methods, leaving 1,569,888 autosomal probes covering 
4,254,946 CpGs spread across 114,984 probe groups. Subsequent pre-processing, 
normalization and correction for batch effects are described in the Statistical Methods 
subsection. CHARM hybridization and processing for these samples were performed 
across 5 separate days, with the following numbers of samples per day: 40, 36, 38, 21, 6, 
reflecting a potential source of batch effects that was addressed through the surrogate 
variable analysis (SVA) described in the Statistical Methods subsection. 
 
b. Infinium HumanMethylation450 assay 
 
For estimating the blood cell type distribution, we performed Infinium 
HumanMethylation450 assay on 147 maternal first trimester period peripheral blood 
buffy coat samples and 90 cord blood buffy coat samples from NCS Vanguard study. 
Isolation of DNA from NCS Vanguard study samples was performed using Agencourt 
Genefind v2 (Beckman Coulter) on the Biomek NXp laboratory automation workstation 
according to manufacturer’s instruction. Genomic DNA from each sample was quantified 




check the quality of extracted DNA. Genomic DNA was normalized/aliquotted to 1ug per 
each sample and sent to Center for Inherited Disease Research (CIDR) for further 
bisulfite conversion of genomic DNA and subjected to Infinium HumanMethylation450 
(Illumina) assay. 
 
c. Bisulphite Pyrosequencing 
 
Individual CpGs inside the DMRs meeting our significance threshold were chosen 
for validation based on MethPrimer software (Li and Dahiya, 2002). Of the 141 samples 
for which CHARM data were generated, 139 had ample DNA for subsequent 
pyrosequencing validation for DMRs associated with gestational age. For replication of 
mercury-associated DMRs, 85 (94%) out of 90 cord blood buffy coat samples from NCS 
Vanguard study, had enough DNA for pyrosequencing. Also, 35 DNA samples extracted 
from a subset of THREE study cord blood clot samples containing TCEANC2 gene 
expression data underwent pyrosequencing inside TCEANC2 DMR. Genomic DNA (200 
ng) from each sample was bisulphite treated using an EZ DNA Methylation-GoldTM Kit 
(Zymo research) according to the manufacturer’s instructions. Bisulphite-treated genomic 
DNA was PCR amplified using unbiased nested primers, and DNA methylation was 
subsequently assessed quantitatively by pyrosequencing using a PSQ HS96 (Biotage). 
Quantitative measurements (percentage methylation at each CpG) from the 
pyrosequencing results were determined using the Q-CpG methylation software (Biotage). 




using appropriate mixtures of Whole Genome Amplified (WGA) Human Genomic DNA: 
Male (Promega) using a REPLI-g Mini Kit (Qiagen) and SSsI-treated WGA DNA. 
Primer sequences used for the bisulphite pyrosequencing reactions can be found in Table 
3.1. 
 
d. Quantitative real-time PCR 
 
To examine the correlation between DNA methylation and gene expression in 
cord blood clots for each of the top three DMRs associated with gestational age and a 
DMR associated with both methyl and total mercury exposure, we performed real-time 
PCR assays. Primers were designed to determine the mRNA expression of the gene 
closest to each DMR. Since this analysis required isolation of mRNA from cord blood 
clots, we were only able to perform these expression analyses on a subset of newborns 
with cord blood clots available. For the genes near gestational age DMRs, there were 10 
babies with gestational age at birth <35 weeks, 15 with gestational age at 40 weeks and 
17 with gestational ages 541 weeks, with a total of 42 samples. For TCEANC2 gene 
containing both methyl and total mercury DMR, we performed the assay on 42 samples 
and removed four babies based on the criteria of Ct standard deviation less than 0.25, 
which reflects maximum Ct difference between the technical replicates is within 1. Thus, 
a total of 38 babies with similar distribution of total and methyl mercury exposure levels 
comparing to the THREE study samples subjected to CHARM 2.0 analysis (methyl 
mercury exposure: 0.92 (0.62-1.34), total mercury exposure: 1.37 (0.85-1.68)). For 




RNA was purified using a PureLinkTM RNA Mini Kit (Invitrogen) according to the 
manufacturer’s instructions. cDNA was synthesized using a QuantiTect Reverse 
Transcription Kit (Qiagen) and random hexamers. Real-time PCR amplification was 
performed by using a Fast SYBR_ Green Master Mix (Applied Biosystems), and 
transcript levels were quantified using an ABI 7900 Sequence Detection Systems 
(Applied Biosystems). Relative expression level for each gene was calculated based on 
the standard curve and normalized by the relative expression of beta-actin. Primer sequences 
used for the real-time PCR reactions are in Table 3.2. 
 
3. Statistical Analyses  
 
 Descriptive statistics (median and interquartile range (IQR)) of THREE study and 
NCV Vanguard study samples were calculated for variables such as sex, maternal age, 
maternal race, gestational age, birthweight, total and methyl mercury levels, and n-3 fatty 
acids. Also, descriptive statistics (median or percentage) for gestational age at birth and 
potential confounders were calculated and compared using chi-squared tests for 
categorical variables and Mann–Whitney U-tests for continuous variables.  
The CHARM microarray data were pre-processed and normalized as previously 
described (Aryee et al., 2011; Jaffe et al., 2012a). We employed a novel statistical 
approach for identifying regions of the epigenome associated with gestational age in days. 
Briefly, we fit a linear model predicting methylation at each probe as a function of either 
gestational age at birth or natural log-transformed methyl/total mercury exposure levels, 




for unmeasured potential confounding often due to batch effects. SVA identifies 
combinations of probes in the data associated with heterogeneity of DNA methylation, 
conditioned on the covariate of interest, in this case, gestational age or methyl/total 
mercury level, and then constructs a ‘surrogate variable’ for each set. A value for each 
individual based on each surrogate variable can then be used for adjustment in 
subsequent regression. Measured variables in our data set most associated with these 
surrogate variables (assessed through pruned regression trees of all possible variables) 
were array quality control score and hybridization date/batch. We did not adjust for sex, 
but did remove sex chromosome probes from the initial genome-wide screen. The 
estimated regression coefficients from these linear models for gestational age at each 
probe were then smoothed within the CHARM array’s pre-defined probe groups. 
Consecutive smoothed slopes above a fixed cut-off of either 99.5
th
 percentile (for 
identification of gestational age DMRs) or 99.995
th
 percentile (for identification of 
mercury level associated DMRs) of all smoothed slopes were summed into a region-level 
statistic reflecting the area of the DMR. We then ranked DMRs by their areas and 
calculated two measures of statistical uncertainty, a P-value and q-value, for each DMR 
by permutation that accounts for genome-wide testing. Either Gestational ages or 
methyl/total mercury exposure levels were permuted 1000 times, and each time, the 
above regression, smoothing, and thresholding procedure was repeated exactly as on the 
observed data to get 1000 sets of declared DMRs that occurred solely by chance. 
Empirical P-values, defined as the fraction of the maximum areas from each permutation 
greater than the observed area, were calculated (Pmax) to compare with a specified family-




mercury DMRs). False discovery rate (FDR) q-values were obtained by pooling all areas 
across all permutations, calculating the proportion of these ‘null’ areas greater than the 
observed area, then converting this to a q-value for comparison to an FDR control of 5% 
(for gestational age DMRs) or 10% (methyl or total mercury DMRs) (Storey and 
Tibshirani, 2003). DMRs with an empirical Pmax < 0.10/0.20 or an FDR q-value < 
0.05/0.1 were examined visually via plots of the methylation curve within the DMR. 
Average methylation for each newborn across all probes within a DMR was plotted 
against gestational age at birth with slopes and P-values estimated via linear regression 
and Wald statistics.  
Univariate relationships between potential confounders and methylation at DMRs 
were also estimated via linear regression. Although some potential confounding due to 
these variables may already be addressed via the SVA adjustment, we also explicitly 
estimated relationships between average DNA methylation for each DMR and each 
confounder through linear models adjusted for the same surrogate variables used in our 
discovery. To do this, we applied SVA analysis to the methylation data first, and then 
took SVA-adjusted methylation as the methylation metric for linear regression with the 
covariate, to ensure the same SVA adjustment was applied in each analysis. Also, as a 
sensitivity analysis to assess the influence of sex on our list of identified DMRs, we 
repeated the original DMR identification procedure adjusting for sex. For gestational age 
DMRs, we further performed the original discovery procedure after omitting samples 
with mothers who had pregnancy-induced hypertension (PIH), intrapartum fever or 
diabetes, separately, to assess influence of these variables on our results. To assess the 




adjusting for race after combining the African Americans and Asians as one race 
category. 
For analysis of DNA methylation data from pyrosequencing, we fit a linear model 
at every CpG inside gestational age DMRs predicting DNA methylation as a function of 
gestational age. For methyl/total mercury DMRs, we fit a linear model at every CpGs 
predicting DNA methylation as a function of log-transformed total or methyl mercury 
exposure. We assessed the functional implications of differential methylation at NFIX, 
RAPGEF2, and MSRB3 gene by fitting linear models at each CpG assessing the linear 
association between DNA methylation and gene expression. For TCEANC2 gene, we 
used spearman’s rank order correlation between DNA methylation and gene expression 
with respect to each CpG. Heavily skewed gene expression values were transformed to 
log2 scale. 
For assessing the relationship between blood cell type distribution and DNA 
methylation at TCEANC2 DMR, we used a publicly available database containing DNA 
methylation signatures for 6 sorted blood cell types (Reinius et al., 2012). Four probe sets 
from the Reinius et al. Illumina 450k dataset (cg01109333, cg01986665, cg02270108, 
and cg02626873), which positioned inside TCEANC2 DMR, were chosen.  We plotted 
the DNA methylation levels at each of these probe set across the sorted blood cell types 
(B cells, CD4
+
 T cells, CD8
+
 T cells, granulocytes, monocytes, natural killer cells, and 
whole blood). For assessing the relationship between blood cell type distribution and total 
mercury exposure levels from NCS Vanguard study samples, we inferred relative cell 
type proportions in this population using an epigenetic signature prediction algorithm 




Table 3.1 Bisulfite Sequencing Primers  
    
       Gene Primer Sequence (5' → 3') Chr CG1 CG2 CG3 
NFIX Forward TTTTTAATTTTTTGTTTTGGGAAAG 19 13131545 13131565 13131573 
  Reverse AAAATAAAAACAACAACAATCCCAC 
    
  Nested_forward TTTTTTTGTTAAGAGAGTTTTGAGG 
    
  Nested_reverse /5Biosg/ATTAAAAAAACAAAACAAAATACAC 
    
  Sequencing 1(F) GTAGGTTTTTGAGGTTTTATTGAGA 
    
  Sequencing 2(F) TTGATTTTTAATTTTTTTTTAGGAG         
MSRB3 Forward AAATTTAAGTATTTTGTTGTGAAAAATTAT 12 65671893 65671906 65671912 
  Reverse AACCAAAAACCTATAAAAAAAC 
    
  Nested_forward TGTTTGGGTTTTATATATGGTGTTTAA 
    
  Nested_reverse /5Biosg/AACAAAAACAAAACTACCAATTAATTACTT 
    
  Sequencing 1(F) TATTTATTTTTTTTTGTTAGAGAGG         
RAPGEF2 Forward TTTTTAAGAATATTGTTTTAAGTGTTAAGT 4 160026608 160026685 160026983 
  Reverse TTTAATAAAACAAATAAACTACCTTCC 
    
  Nested_forward TTTTTTTGGTTGTTTTTGGATAAGT 
    
  Nested_reverse CCATAATCTCCCAAATATAACAACTC 
    
  Forward2 TTTTTTTTGATGTTGATTATTATTTAT 
    
  Reverse2 AAAATCTACTTTTCCTTCACACTAAAAC 
    
  Nested_forward2 TTGTGGGGAGAGTATAATAAAATAGATTT 
    
  Nested_reverse2 /5Biosg/AAAACAAAATCAATACAAAACATTCCT 
    
  Sequencing 1(F) GATAAGTTTTAAGAGTGGTATTTGGT 
    
  Sequencing 2(F) TGTTTTTGGATAAGTTTTAAGAGTG 
    
  Sequencing 3(F) TATTTGGGAGATTATGGATAGATTG         




  Reverse ATCCTTAACATATTCACAATAAAAT 
      Nested_forward TTGATGTTGGTTGTGTTAGATTTTT 
      Nested_reverse /5biosg/CATCACCCTTTCACCATATTAAATAATA 
      Sequencing 1(F) GTAGGAATGTGTTTTATTAGTTGTA 
      Sequencing 2(F) GTTGGTTGTGTTAGATTTTTTTATG         
ANGPT2 Forward1 AGAATTGTGTTGTTGTTTTTTGTGT 8 6418033 6418040 6418044 
  Reverse1 AACTCCACACCTATTCTCCCAA 
      Nested_forward1 TTATAGGTGATAAAATATAGGAGAAAAATA 
      Nested_reverse1 /5biosg/CCTAAAAAAAACAATTTACACTCTC 
      Forward2 GTGTAAATTGTTTTTTTTAGGTGTA 
      Reverse2 ATAAACAAAACTCATATTTCTTTCTTAAAT 
      Nested_forward2 TTGGGAGAATAGGTGTGGAGTT 
      Nested_reverse2 /5biosg/TAAACAACAATAACACAATAATATTTCAAA 
      Forward3 TAGTTTTGTATTTGGTTTAGTATTT 
      Reverse3 ATCACTATAATTTACTTTTAAACATCTTCT 
      Nested_forward3 TTTTTATGTTTTTTGGTTGTTTTTT 
      Nested_reverse3 /5biosg/TAATTAATAACTTTCCCACATCCAC 
      Sequencing 1(F) TTTGTTTTTATTTTTAAGTTAGAAG 
      Sequencing 2(F) GATAAATATTAAGTTATTTTTGGGG 
      Sequencing 3(F) GTAGATTAGAATATTTATTGTAGTG         
PRPF18 Forward1 TTGTTGATTTTTTATTTTTGGGAATA 10 413684055 413684060 413684275 
  Reverse1 CCAAAATACCATTTCAAAAAAACTC 
      Nested_forward1 TTTTTTATAAATGTGGTTGTGTGTTT 
      Nested_reverse1 /5biosg/AATCTCCAACAAAATCATTTCACTAC 
      Forward2 TTATTATAATTTTATGGGTTTTTGAAATTA 
      Reverse2 CAAACAATAAATCTCCAACAAAATC 
      Nested_forward2 TAGGTTTTTTAGTTTTGTTGGAGTA 




  Nested_reverse2 /5biosg/CACACAACCACATTTATAAAAAAAA         
FOXD2 Forward1 TTTTTTGGGTATTTTTTTTATTTGTTT 1 48059802 48059934 48060162 
  Reverse1 CACCCTCATCTTAAAACTAAAACTCA 
      Nested_forward1 GGAGTTTTTATGAAGGTTTAGGGTT 
      Nested_reverse1 /5biosg/TAAACAACAAAACAAAATTTACACCA 
      Forward2 GGTTTTTAAATTTATTTTTTATGTTTTTAT 
      Reverse2 ACCACTCCTTTCTAACAAATTAACT 
      Nested_forward2 TTTTAAAAGTATTAGAGAGAGGTTGGAATA 
      Nested_reverse2 /5biosg/AAAAAAACACCAAACAAAACCTTAC 
      Forward3 AAGGTTTTGTTTGGTGTTTTTTTTA 
      Reverse3 CACCAACACTAAAAATCAAATTTCA 
      Nested_forward3 TTTTTAGTTGGGTAATGGGGTTAG 
      Nested_reverse3 /5biosg/CCAACTCTTAAAAAATACCCACTTC 
      Sequencing 1(F) GATAGAGATTGAGTAGTAGTGGAGG 





Table 3.1 Bisulfite Sequencing Primers 
continued  
     
         Gene Primer CG4 CG5 CG6 CG7 CG8 CG9 CG10 
NFIX Forward 13131612   
       Reverse 
  
       Nested_forward 
  
       Nested_reverse 
  
       Sequencing 1(F) 
  
       Sequencing 2(F)               
MSRB3 Forward 65671924 65671942 
       Reverse 
  
       Nested_forward 
  
       Nested_reverse 
  
       Sequencing 1(F)               
RAPGEF2 Forward 
  
       Reverse 
  
       Nested_forward 
  
       Nested_reverse 
  
       Forward2 
  
       Reverse2 
  
       Nested_forward2 
  
       Nested_reverse2 
  
       Sequencing 1(F) 
  
       Sequencing 2(F) 
  
       Sequencing 3(F)               
TCEANC2 Forward 54562368 




  Reverse 
         Nested_forward 
         Nested_reverse 
         Sequencing 1(F) 
         Sequencing 2(F)               
ANGPT2 Forward1 6418111 6418147 6418172 6418449 6418469 6418511 6418530 
  Reverse1 
         Nested_forward1 
         Nested_reverse1 
         Forward2 
         Reverse2 
         Nested_forward2 
         Nested_reverse2 
         Forward3 
         Reverse3 
         Nested_forward3 
         Nested_reverse3 
         Sequencing 1(F) 
         Sequencing 2(F) 
         Sequencing 3(F)               
PRPF18 Forward1 
         Reverse1 
         Nested_forward1 
         Nested_reverse1 
         Forward2 
         Reverse2 
         Nested_forward2 




  Nested_reverse2               
FOXD2 Forward1 48060221 48060268 
       Reverse1 
         Nested_forward1 
         Nested_reverse1 
         Forward2 
         Reverse2 
         Nested_forward2 
         Nested_reverse2 
         Forward3 
         Reverse3 
         Nested_forward3 
         Nested_reverse3 
         Sequencing 1(F) 






Table 2. Real-time PCR Primers for Expression Analyses 
   
Gene Primer Sequence (5' → 3') 
NFIX Forward AGGAGATGCGGACATCAAA 
  Reverse TACTCTCACCAGCTCCGTCA 
MSRB3 Forward AGTAGCCCTTCGAGCCTGT 
  Reverse GTTAGCCGCTTCCTCAGTTC 
RAPGEF2 Forward CAGACAAAGCACATCCCAAC 
  Reverse TGGCAAGTCAGGAGTAGCAC 
TCEANC2 Forward CAGCTACCAGGGCTGCTT 
  Reverse GGGACTCCGACTACCTTGAC 
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Chapter 4: Results – 
Identification of gestational age DMRs 
 
 
This chapter is reproduced from published article in International Journal of 












To identify epigenetic changes that occur throughout later stages of gestation in 
an unselected population of newborns, we performed the CHARM 2.0 assay, which now 
includes approximately one-third of all single-copy CpG sites including all islands and 
shores, as well as all annotated promoters and microRNAs. Bisulphite pyrosequencing 
and real-time PCR were performed to validate DNA methylation levels and functional 
significance of the DMRs associated with gestational age at birth. Of the 141 newborns 
with CHARM data, there were 18 PTBs (<37 weeks) and the range of gestational ages in 
days was 208–292 (Figure 4.1 for full distribution). The pre-term newborns did not differ 
in the distributions of sex or maternal age, race or diabetes status compared with 
newborns born after 37 weeks (Table 4.1). Birthweight differed strongly between the two 
groups, as did smoking and serum copper levels, which had been previously reported for 
the full study sample of 300 newborns (Wells et al., 2011).  
Previous research indicates that increasing gestational ages at birth through 39–41 
weeks is advantageous for neurodevelopment (Davis et al., 2011; Yang et al., 2010) and 
confers a lower risk of respiratory morbidity (Hansen et al., 2008), suggesting the need to 
study gestational age on a continuum. Thus, treating gestational age as a continuous 
variable in linear regression, compared with pre-term and term birth categories can be 
useful. Using this approach, we identified 8611 candidate DMRs associated with 
gestational age at birth (top 30 showed in Table 4.2), of which the top three DMRs met 
our genome-wide threshold of protecting family-wise error rates <10% and false 
discovery rates <5% (Table 4.3). The first of these DMRs was found to be positioned in 
the first intron of the nuclear factor I/X (NFIX) gene, encoding a transcription factor 




development (Messina et al., 2010). Another was positioned in the first intron of the 
alternative transcript of the Rap guanine nucleotide exchange factor (RAPGEF2) gene, 
which encodes one of the RAS protein family activators that maintains the GTP-bound 
state of RAS. Although this DMR was not located at the promoter of the canonical gene, 
the DMR contains strong DNase I hypersensitive sites and a number of strong 
transcription factor-binding sites including Gata-2 and PU.1, which are the critical 
transcription factors in haematopoiesis (Ramirez et al., 2010; Vicente et al., 2012). The 
third DMR was located next to the promoter region of the methionine-Ssulphoxide 
reductase 3 (MSRB3) gene, which encodes the enzyme involved in the methionine cycle 
and is responsible for antioxidant repairing by converting methionine sulphoxide to 
methionine (Marchetti et al., 2005). Two of the three DMRs are located at the CpG island 
shore, suggesting that these DMRs may be associated with alternative transcription or 
splicing.  
The methylation values at each probe for each of these DMRs are shown in Figure 
4.2 according to gestational age in weeks (calculated from days). Smoothed lines indicate 
the average methylation curve for each week of gestational age at birth, and show a dose–
response trend between gestational age and methylation levels across all weeks for each 
DMR. To further illustrate this point, Figure 4.2 also shows the relationship between the 
average methylation across all probes in the DMR and gestational age, and the linear fit 
of this relationship (see insets in each panel). For the DMR near NFIX, DNA methylation 
levels of each probe are greater in high gestational age neonates when compared with low 
gestational age neonates (Figure 4.2a), and the average DNA methylation level of each 




increase of 1.57% DNA methylation per week of gestation [95% confidence interval (CI) 
1.02–2.12], or an increase of 7.85 between Weeks 35 and 40, roughly corresponding to 
late pre-term vs term births (P=8.6X10
8
 for Wald statistic; see Figure 4.2a, inset). In 
contrast, the DMRs at RAPGEF2 and MSRB3 show lower DNA methylation levels of 
each probe in higher gestational age neonates when compared with lower gestational age 
neonates (Figure 4.2b and c), and the average DNA methylation levels of each sample in 
these DMRs exhibit inverse linear correlation with gestational age. For RAPGEF2, there 
is a 1.33 decrease in %DNA methylation (95% CI -1.76 to -0.9) per week of gestation or 
a decrease of 6.65 between Weeks 35 and 40; (Wald P=9.9X10
9
) and for MSRB3, a 2.08 
decrease (95% CI -2.51 to -1.64) per week or 10.4 between Weeks 35 and 40 (Wald 
P=1.3X10
16
; see Figure 4.2b and c insets). Also note the progressive change in DNA 
methylation within each gestational age bin, a dose–response relationship consistent with 
a functional relationship between methylation and gestational age.  
To validate these findings on a separate platform, we designed bisulphite 
pyrosequencing assays for CpGs within each DMR (indicated as red blocks in Figure 4.2). 
The individual CpG results within each DMR were correlated (average pair-wise 
correlation for neighboring CpG methylation was 0.85 for NFIX, 0.68 for RAPGEF2 and 
0.82 for MSRB3) and confirmed the CHARM differences in methylation by gestational 
age. For NFIX, four CpGs were assayed (see Figure 4.2 for locations), each showing an 
incremental increase in methylation with increase in gestational age at birth, consistent 
with the pattern detected in CHARM (Figure 4.3a). All three of the CpGs assayed in 
RAPGEF2 (see Figure 4.2 for locations) showed greater methylation with early 




all five CpGs assayed showed greater methylation in earlier gestational age samples as 
seen in CHARM (Figure 4.3c). Thus, these DNA methylation analyses on an independent 
measurement platform confirmed the differential methylation by gestational age for each 
of the three genes identified via CHARM.  
Since the three DMRs we identified reflect variability in methylation 
corresponding to late-stage development in utero, we considered whether adult DNA 
methylation at these same sites would show any variability and whether adult levels 
would be similar to those of full-term births. We compared CHARM 2.0 data for each 
DMR among healthy adult blood DNA samples with our newborn sample results. 
Although the three DMRs appear very dynamic and progressive with gestational age in 
the newborn sample, these exact same regions have little variability in the adult 
population. Given the span of adult ages represented, this suggests that these sites are 
stable in adulthood. The magnitude of adult DNA methylation levels is similar to or more 
extreme than those of the latest gestational ages in a direction consistent with the 
newborn sample correlations to gestational age (Figure 4.4). These results provide 
compelling support for maturation-related  hanges in DNA methylation at these loci, and 
also indicate that the process continues beyond birth, but reaches a maximum at some 
time at or before adult life.  
To address potential confounding by sex, maternal age, race, maternal smoking, 
presence of PIH, intrapartum fever, maternal smoking and serum copper levels, we 
estimated the linear relationships between each of these variables and gestational age at 
birth. Consistent with the general characteristics comparing pre-term babies to the rest of 




age (Table 4.4). To further address whether these potential confounders were associated 
with methylation at the identified DMRs, we estimated the linear relationship between 
these variables and the average methylation value per DMR as well. PIH and serum 
copper were also associated with methylation at each of these DMRs (Table 4.4), 
suggesting the potential for confounding. However, the strong association between 
methylation and gestational age remained even after adjusting for PIH and copper in both 
CHARM and pyrosequencing data. For example, in the CHARM data, the coefficient for 
gestational age at birth in linear models predicting average methylation at each DMR 
with and without adjustment for copper (which had a stronger effect than PIH) changed 
from 1.57 to 1.37 for NFIX, -1.33 to -1.17 for RAPGEF2 and -2.08 to -1.87 for MSRB3, 
and all remained statistically significant. We in fact examined the potential influence of 
each potential confounder on the detected associations with these three DMRs and saw 
no substantial change in effect sizes after adjustment for any of these covariates (Table 
4.5).  
Birthweight was also correlated with both gestational age and with methylation at 
each of the three DMRs. This is expected given the strong relationship between 
gestational age and birthweight. Gestational age is the best indicator of maturation of the 
newborn including growth parameters. Since birthweight is largely a consequence of 
gestational age, removing birthweight variability would almost completely restrict 
variability for gestational age in our analyses, so we did not condition on birthweight for 
these analyses. When we considered birthweight for gestational age as a separate 




To explore the functional significance of the differential methylation, we 
measured the expression of the NFIX, RAPGEF2 and MSRB3 using real-time PCR. 
RAPGEF2 showed an inverse linear correlation between expression and DNA 
methylation levels in two of the three CpGs at this DMR (CpG1: P=0.37; CpG2: P=0.013, 






























Figure 4.2 Methylation plots for three identified DMRs for gestational age at birth.  
 
(a) NFIX, (b) RAPGEF2, (c) MSRB3. Top half of panels show individual methylation 
levels at each probe by genomic position, with coloured lines reflecting the average 
methylation curve for samples binned by gestational age—gestational ages in weeks were 
split into equal sized bins, and the average age for each bin is shown in the legend. 
Bottom half of panels show location of CpG dinucleotides (black tick marks) and CpGs 
validated by bisulphite pyrosequencing (black tick marks contained in red box) as well as 
the CpG density by position (black curve) and the location of refseq annotated genes (bar, 
+ and - represent the direction of the gene, green bar indicates CpG island). Vertical lines 
represent boundaries of the DMR. Inset box: linear regression plot of average  







Figure 4.3 Bisulphite pyrosequencing results for each DMR.  
 
(a) NFIX, (b) RAPGEF2, (c) MSRB3. Circles represent methylation values (y-axis) at individual CpGs for their corresponding 
gestational age in weeks (x-axis). Lines represent predicted values from linear regression. Reconstitution controls (represented as 
black dots) with explicitly designed % methylation (x-axis) are located at the right of each panel (Recon). The numbers on the bottom 








Figure 4.4 Methylation plots for three identified DMRs for gestational age at birth 
with adult methylation results included. 
Individual adult methylation levels are represented as grey lines, and the black line 








Figure 4.5 Correlations between gene expression and DNA methylation for each DMR and its nearest gene.  
Panel A: NFIX, panel B: RAPGEF2, panel C: MSRB3. Black dots represent methylation values (y-axis) at individual CpGs and their 
corresponding normalized expression level (x-axis). Lines represent fit of a linear regression. The numbers on the bottom of each 




















19 NFIX 0.343 0.010 1.0E-03 1.2E-03 13130686 13133039 inside intron 
4 RAPGEF2 0.223 -0.008 4.7E-02 2.9E-02 160026138 160028079 upstream 
12 MSRB3 0.197 -0.014 9.8E-02 4.1E-02 65671230 65672140 promoter 
8 INTS10 0.160 -0.010 2.3E-01 8.8E-02 19615409 19616461 upstream 
10 C10orf140 0.147 0.008 3.2E-01 9.4E-02 21803713 21804972 inside exon 
3 IQSEC1 0.144 -0.006 3.5E-01 9.4E-02 12937650 12939468 overlaps 3' 
14 BCL11B 0.138 0.007 4.1E-01 9.8E-02 99725056 99726396 inside intron 
4 LEF1 0.132 0.006 4.7E-01 1.0E-01 109085956 109087500 covers exon(s) 
6 PREP 0.130 0.007 5.1E-01 1.0E-01 106034980 106036264 upstream 
14 BCL11B 0.122 0.006 5.8E-01 1.0E-01 99706752 99708241 inside intron 
12 LEMD3 0.120 -0.010 6.1E-01 1.0E-01 65564532 65565296 overlaps exon downstream 
1 C1orf83 0.118 -0.005 6.4E-01 1.0E-01 54561298 54563187 overlaps exon upstream 
19 UQCRFS1 0.116 -0.006 6.7E-01 1.0E-01 29696666 29697995 downstream 
4 TRIM2 0.115 0.005 6.8E-01 1.0E-01 154125212 154126966 overlaps 5' 
17 TNFSF13 0.114 -0.009 7.0E-01 1.0E-01 7462633 7463465 covers exon(s) 
14 BCL11B 0.112 0.005 7.2E-01 1.0E-01 99709752 99711218 inside intron 
14 FBLN5 0.112 -0.006 7.2E-01 1.0E-01 92412243 92413573 overlaps exon downstream 
5 CRHBP 0.107 -0.012 7.8E-01 1.2E-01 76248520 76249150 overlaps 5' 
8 DEFA4 0.101 -0.006 8.6E-01 1.2E-01 6792265 6793315 close to 3' 
14 APEX1 0.100 -0.007 8.6E-01 1.2E-01 20924708 20925624 covers exon(s) 
6 WRNIP1 0.100 -0.007 8.6E-01 1.2E-01 2769840 2770750 covers exon(s) 
1 ITPKB 0.098 0.005 8.8E-01 1.2E-01 226900271 226901597 inside intron 
3 IFT80 0.097 0.007 8.9E-01 1.2E-01 159941894 159942728 downstream 




14 RNASE10 0.096 -0.006 9.0E-01 1.2E-01 20978625 20979745 covers 
3 CTDSPL 0.095 -0.006 9.0E-01 1.2E-01 37904056 37905258 inside intron 
14 NPAS3 0.095 0.006 9.0E-01 1.2E-01 33400717 33401757 upstream 
13 DLEU2 0.095 0.008 9.0E-01 1.2E-01 50702836 50703608 upstream 












Table 4.4. Co-efficient (95% CIs) of linear relationship between potential confounders and gestational age at birth or average 






Table 4.5. Comparison of regression coefficients [95% CI] for relationship between 
methylation and gestational age with and without adjustment for potential 
confounders 
Model: M* = b1GA + b2Z 
     NFIX RAPGEF2 MSRB3 
Z b1 b1 b1 
N/A (unadjusted) 1.57 [1.02,2.12] -1.33 [-1.76,-0.90] -2.08 [-2.51,-1.64] 
Copper 1.37 [0.79,1.94] -1.17 [-1.62,-0.72] -1.87 [-2.32,-1.42] 
Male sex 1.54 [1.03,2.05] -1.32 [-1.74,-0.89] -2.07 [-2.51,-1.63] 
PIH 1.39 [0.82,1.95] -1.25 [-1.70,-0.80] -2.00 [-2.45,-1.54] 
Smoking 1.75 [1.17,2.34] -1.47 [-1.93,-1.00] -2.25 [-2.71,-1.79] 







Table 4.6. Results for univariate and multivariate regression analyses of methylation on birthweight and/or gestational age 
DMR Model b1 pval   b2 pval 
NFIX M* = b1GA 1.57 8.0E-08 
   
 
M* = b1BW 0.0029 5.0E-03 
   
 




M* = b1(BW|GA) -0.0007 0.62 
   
       RAPGEF2 M* = b1GA -1.33 9.9E-09 
   
 
M* = b1BW -0.0029 3.0E-04 
   
 
M* = b1BW + b2GA -0.0002 0.80 
 
-1.28  8.7e-06 
 
M* = b1(BW|GA) -0.0002 0.83 
   
       MSRB3 M* = b1GA -2.07 1.3E-16 
   
 
M* = b1BW -0.0040 1.4E-05 
   
 
M* = b1BW + b2GA 0.0005 0.57 
 
-2.20  1.9e-12 
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Chapter 5: Results – Identification of 











To identify candidate genomic regions showing epigenetic differences associated 
with total and methyl mercury exposure, we utilized previously obtained CHARM 2.0 
DNA methylation data originally used for identifying gestational age DMRs (Lee et al., 
2012). Descriptive statistics for Baltimore THREE and NCS Vanguard cohort samples 
used for this study are given in Table 5.1. Distribution of sex and gestational age between 
the two cohorts were similar. Higher maternal age and birthweight were observed in NCS 
Vanguard cohort. Total and methyl mercury exposures are higher in THREE cohort 
samples, which further described in Table 5.2. Although the distribution is different, both 
cohorts only contain two samples with methyl mercury exposure levels higher than the 
reference dose (5.8ug/L), suggesting the exposure levels in both cohorts are within the 
normal exposure range. Both cohorts also display different race distribution, which 
African Americans are dominant in THREE cohort, whereas Caucasian contributes as a 
major population in NCS Vanguard cohort. Uniquely, n-3 fatty acids (EPA and DHA), an 
essential nutrient for healthy neurological development and may counter the toxic effect 
from mercury exposure (National Research Council, 2007), were measured in THREE 
cohort to assess n-3 fatty acids as a potential confounder. 
Since methyl mercury exposure as a most relevant mercury species related to 
adverse health outcomes and site-specific DNA methylation changes shown to be 
associated with methyl mercury exposure levels (Basu et al., 2013; Goodrich et al., 2013), 
we sought to first identify DMRs associated with methyl mercury exposure after natural 
log transformation of the exposure data due to its lognormal distribution. By this 
approach, we identified 130 candidate DMRs associated with methyl mercury exposure, 




genome-wide threshold of family wise error rates < 20% and false discovery rate < 10% 
(Table 5.3). The candidate DMR with genome-wide significance was located in the exon 
of Transcription Elongation Factor A (SII) N-Terminal And Central Domain Containing 
2 (TCEANC2) gene, which encodes a putative transcription elongation factor. 
Figure 5.1 demonstrates the methylation plots for TCEANC2 DMR negatively 
associated with either methyl (Figure 5.1a) or total (Figure 5.1b) mercury exposure. Each 
dot represents the methylation values at each probe for each neonate sample. Smoothed 
line represents the average methylation curve for each exposure level quartile, which 
show dose-dependent negative trend for both types of the exposure levels. Methylation 
plots for the other three candidate DMRs associated with total mercury exposure are 
shown in Figure 5.2 a-c, and Figure 5.2 d-f represents the overlapping regions plotted by 
quartiles of methyl mercury exposure. The DMR inside ANGPT2, which encodes 
Angiopoietin 2, represents positive correlation between the methylation and both of the 
exposure levels. Negative association between the methylation and exposure levels for 
both total and methyl mercury were shown in DMR inside PRPF18 gene, encoding Pre 
mRNA Processing Factor 18, and DMR near FOXD2 gene, which encodes a transcription 
factor Forkhead Box D2. 
To replicate these findings on a separate methylation assay platform, bisulphite 
pyrosequencing assays were performed on four CpGs within the TCEANC2 DMR (red 
blocks in Figure 5.1). DNA methylation at all of the four CpGs displayed decrease in 
DNA methylation level along with increase in both methyl mercury (Figure 5.3a) and 
total mercury (Figure 5.3b) exposure level, consistent with the pattern detected in 




and exposure levels identified by CHARM 2.0 is replicated using an independent 
measurement platform with independent set of cohort samples. Other three DMRs which 
displayed association between DNA methylation and total mercury exposure were also 
tested for replication via bisulfite pyrosequencing (Figure 5.4). The DNA methylation 
trend identified from the CpGs inside three DMRs was not consistent with the pattern 
detected from CHARM 2.0, meaning that the other three DMRs weren't able to replicate. 
To address potential confounding by sex, maternal age, race, birthweight, 
gestational age and lead, selenium, copper and n-3 fatty acid levels, we estimated the 
linear association between each of these variables and total or methyl mercury exposure 
level obtained from THREE study samples. Consistent with the previous reports (Wells 
et al., 2011), race and n-3 fatty acid levels were associated with both types of mercury 
exposure levels (Table 5.4). We then also estimated the linear relationship between these 
potential confounders and the average methylation level at TCEANC2 DMR to further 
address for potential confounding. Race, not n-3 fatty acid level, was also associated with 
methylation at TCEANC2 DMR, suggesting the potential for confounding. However, the 
association between average methylation at the DMR and total or methyl mercury 
exposure levels after adjusting for race (Table 5.5) remained statistically significant even 
after adjusting. 
Different cell type distribution has been suggested as a potential confounder, in 
particular for DNA methylation studies using whole blood samples due to cell type 
distribution shifts due to the nature of the disease or the exposure, and has been addressed 
in several publications (Joubert et al., 2012; Liu et al., 2013). To examine whether the 




cell type, we used a publicly available database containing DNA methylation signatures 
for sorted blood cells (Reinius et al., 2012). Within or near our DMR (chr1: 54562102 – 
54562548), there were four probe sets from the Illumina 450k dataset (cg01109333, 
cg01986665, cg02270108, and cg02626873). We plotted the DNA methylation levels at 
each of these probe sets across the sorted blood cell types (B cells, CD4+ T cells, CD8+ 
T cells, granulocytes, monocytes, natural killer cells, and whole blood) (Figure 5.5). 
There were six replicates of each cell type. Across three of the probe sets, DNA 
methylation was not heterogeneous and there was no relationship between cell type and 
DNA methylation. For one of the probe sets (cg01986665), DNA methylation levels were 
heterogeneous and there was some variability across cell type. It is possible that DNA 
methylation varies by cell type at this locus. 
To address whether the relationship between DNA methylation and mercury to be 
confounded by cell type, we looked to our Infinium HumanMethylation450 assay data 
from NCS Vanguard study samples. We were able to infer relative cell type proportions 
in this population using an epigenetic signature prediction algorithm (Houseman et al., 
2012). Maternal blood total mercury levels measured during first trimester were not 
associated with proportions of cell types inferred by DNA methylation levels in maternal 
first trimester whole blood buffy coat samples, as well as by cord blood buffy coat 
samples (Table 5.6). Since there was no relationship observed between estimated blood 
cell distribution and total mercury levels, cell type thus is not a confounder of the DNA 
methylation and mercury association in our study. 
To examine the functional significance of the methylation difference at 




time PCR assay. All of the four assessed CpGs show an inverse correlation between 
expression and DNA methylation levels, although not statistically significant (spearman 





















Figure 5.1. Methylation plots for DMR inside TCEANC2 associated with methyl and 
total mercury exposure  
(a) TCEANC2 DMR with color codes representing quartiles of methyl mercury exposure 
and (b) total mercury exposure. Top half of panels show individual methylation levels at 
each probe by genomic position, with colored lines reflecting the average methylation 
curve for samples. The median exposure level for each quartile is shown in the legend. 
Bottom half of panels show location of CpG dinucleotides (black tick marks) and CpGs 
validated by bisulphite pyrosequencing (black tick marks contained in red box) as well as 
the location of refseq annotated genes (bar, + and - represent the direction of the gene, 







Figure 5.2. Methylation plots for other identified DMRs associated with total 
mercury exposure  
(a), (b), and (c) represent DMR inside or near ANGPT2, PRPF18 and FOXD2 with color 
codes representing quartiles of total mercury exposure. (d), (e), and (f) represents same 






Figure 5.3. Bisulfite pyrosequencing results for DMR inside TCEANC2  
 
Circles represent methylation values (y-axis) at individual CpGs for their corresponding 
methyl mercury exposure levels (a) or total mercury exposure levels (b) on the x-axis. 
Fitted lines represent predicted values from linear regression. Reconstitution controls 
(represented as black dots) with predicted % methylation (x-axis) are located at the right 
bottom corner (Recon). The numbers on the top of each figure represent effect size/slope 
estimate from the regression of methylation on mercury expsosure and P-value for a 








Figure 5.4. Bisulfite Pyrosequencing Results for DMR inside ANGPT2, PRPF18 and 
near FOXD2 
 
Pyrosequencing results for (a) ANGPT2, (b) PRPF18, and (c) FOXD2. Circles represent 
methylation values (y-axis) at individual CpGs for their corresponding total mercury 







Figure 5.5. DNA methylation levels at four Infinium HumanMethylation450 probe 
sets located near/inside the DMR inside TCEANC2 
Each box represents the four probes near or inside the TCEANC2 DMR. Boxplots 
represent percent methylation levels (y axis) for each given blood cell types (x axis). The 
labels on the top of each box represent the probe ID assigned on the 








Figure 5.6. Correlation between DNA methylation level at TCEANC2 DMR and 
TCEANC2 gene expression level 
Circles represent the normalized expression level of TCEANC2 (x axis) with respect to 
DNA methylation level (y axis) for each CpG subjected to pyrosequencing. Fitted line 
represents predicted values from linear regression. The numbers on the top of each figure 







Table 5.1. Characteristics of THREE and NCS Vanguard study newborns included 








Table 5.2. Distribution of total/methyl mercury from THREE and NCS Vanguard 








Table 5.3. Candidate significant DMRs associated with total (a) and methyl (b) 






Table 5.4. Linear relationship coefficient [95%CI] between potential confounders 
and total (a) and methyl (b) mercury exposure or average methylation at DMR 







Table 5.5. Comparison of regression coefficients [95% CI] for association between 
DNA methylation and total (a)/methyl (b) mercury exposure with and without 













Correlation 95% CI Mean (IQR) 
Maternal Trimester 1   
CD8+ T cells -0.0512 (-0.22, 0.12) 1.74 (0,2.45) 
CD4+ T cells 0.0465 (-0.12, 0.21) 10.39 (7.77,12.32) 
Natural killer cells -0.0012 (-0.17, 0.17) 4.7 (2.46,6.62) 
B cells 0.1116 (-0.06, 0.27) 4.89 (3.45,5.96) 
Monocytes -0.1019 (-0.26, 0.07) 9.74 (8.22,11.09) 
Granulocytes -0.0020 (-0.17, 0.17) 61.63 (57.42,67.39) 
Fetal Cord Blood    
CD8+ T cells -0.1250 (-0.33, 0.10) 2.14 (0,3.77) 
CD4+ T cells -0.0803 (-0.29, 0.14) 14.15 (10.27,17.67) 
Natural killer cells -0.1783 (-0.38, 0.04) 5.73 (1.57,9.31) 
B cells -0.0540 (-0.27, 0.17) 13.05 (9.93,15.35) 
Monocytes 0.1833 (-0.04, 0.39) 11.8 (9.71,13.04) 
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Using a genome-wide custom DNA methylation array technology and novel 
statistical methods, we have identified three differentially methylated regions associated 
with gestational age at birth and one DMR associated with both methyl and total mercury 
exposure level. Array-based methylation results for all three regions were validated or 
replicated via bisulphite pyrosequencing.  
DMRs associated with gestational age target areas of the genome likely to be 
under developmental regulation in late gestation, which may have implications for 
understanding the reasons for immediate as well as long-term health effects of gestational 
age at birth. The observed incremental progression between methylation and gestational 
age at birth is further supported by the observation that adults are not variable at these 
DMRs, but rather appear to be stable at levels similar to or more extreme than newborns 
with the latest gestational ages at birth. The genes nearest the identified DMRs may play 
important roles in late-stage fetal development. NFIX is known to be responsible for 
regulating skeletal muscle (Messina et al., 2010), brain and bone development (Campbell 
et al., 2008; Driller et al., 2007; Mason et al., 2009), which show substantial  growth 
during late gestation. This finding offers face validity that our approach can identify 
epigenomic regions relevant to late gestational development. RAPGEF2 plays a critical 
role in embryonic haematopoiesis (Satyanarayana et al., 2010) and brain development (i.e. 
commissures) (Bilasy et al., 2011). Although this DMR was not located at the promoter 
of the canonical gene, the DMR contains strong DNase I hypersensitive sites and a 
number of strong transcription factor-binding sites including Gata-2 and PU.1, which are 
the critical transcription factors in haematopoiesis (Ramirez et al., 2010; Vicente et al., 




low B-cell function (given ready transplacental passage of maternal antibodies) as well as 
lower platelet counts than seen in babies (born at term). This methylation change with 
gestational age could be involved in the ontogeny of the haematopoietic system and the 
switch from production of erythrocytes to increased production of B-lymphocytes and 
megakaryocytes in preparation for birth and, respectively, secretion of antibodies in 
response to antigenic assaults as well as production of platelets to prepare for possible 
birth trauma. Furthermore, anaemia of prematurity is known to cause morbidity in pre-
term infants; disruption of regulation of this system may contribute to anaemia of 
prematurity, due to higher haematocrits and restricted erythropoiesis at birth. The 
differential methylation detected in our newborn sample did correlate with expression of 
RAPGEF2 in cord blood cells, lending support for involvement in development of the 
haematopoietic system. Finally, MSRB3 encodes a methionine sulphate reductase enzyme 
involved in antioxidant repair, converting methionine sulphoxide to methionine. This 
specific reductase has been found to be present in many tissues including the human lens 
and the cochlea and has been suspected to be involved in cataracts caused by oxidative 
damage to lens cells (Marchetti et al., 2005). Most congenital cataracts are idiopathic; 
however, PTB and the administration of certain drugs in utero have been identified as 
risk factors (Rahi and Dezateux, 2000), pointing to a possible role for oxidative stress for 
cataract formation in infants as well as adults. Generally, a number of morbid conditions 
associated with term birth have been tied to oxidative stress, from administration of 
oxygen, including retinopathy of prematurity, bronchopulmonary dysplasia, necrotizing 
enterocolitis and intraventricular haemorrhage (Walsh et al., 2009). MSRB3 and other 




stress. Mutations in MSRB3 also cause hereditary deafness (Ahmed et al., 2011) and 
variants in this gene have been associated with primary tooth development during infancy 
in a recent genome-wide association study (Pillas et al., 2010).  
The DMR associated with both methyl and total mercury target TCEANC2 gene 
which encodes Transcription Elongation Factor A (SII) N-Terminal And Central Domain 
Containing 2, a hypothetical transcription elongation factor based on the sequence 
domain homology. Although no publication in regards to the function of TCEANC2 
protein itself has yet been reported, methyl mercury can increase RNA synthesis in vitro 
at least partly through stimulating chain elongation by RNA Polymerase II (Chao and 
Frenkel, 1983; Frenkel and Ducote, 1987; Frenkel and Randles, 1982). Together with the 
negative association between TCEANC2 gene expression and methylation changes at the 
DMR from our result, there is a possibility of potential function for TCEANC2 by 
mediating between the methyl mercury exposure and increase in RNA transcription.    
These results do not appear to be sensitive to confounding by measured variables. 
Furthermore, it is possible that methylation may be part of the mechanism relating factors 
to gestational age at birth or mercury exposure levels. In these cases, one would not want 
to adjust for such factors in analysis. Thus, we were conservative in our approach to 
adjustment. Nonetheless, inclusion of potential confounders in our models did not 
attenuate the relationship between methylation and gestational age or mercury exposure 
levels at these DMRs. Our use of SVA to reduce the impact of measurement issues, such 
as batch effects, may also have adjusted for potential residual confounding not captured 
by a measured variable. It is worth noting that serum copper levels have previously been 




confounder. Nonetheless, the relationship between DMR methylation and gestational age 
did not attenuate after adjustment for copper. We did, however, observe a relationship 
between copper levels and methylation in these adjusted models, suggesting an 
independent effect of copper on methylation, consistent with the growing interest in 
environmental impacts on the epigenome and their implications for human health 
(Dolinoy and Jirtle, 2008; Sutherland and Costa, 2003). We also observed a relationship 
between race and methylation in adjusted model, also suggesting an independent effect of 
race on methylation at TCEANC2 DMR. Although we saw a relationship between 
birthweight and gestational age DMRs, this appeared to be a function of the relationship 
between gestational age and birthweight, rather than specific to birthweight itself. 
Although a recent report did see a relationship between global DNA methylation and 
birthweight for gestational age (Michels et al., 2011), we did not see an association with 
these particular DMRs when considering birthweight adjusted for gestational age 
(Supplementary Table 5).  
An important caveat in this study is that we measured DNA methylation from a 
surrogate tissue, blood, for which methylation changes may not reflect those of tissues 
undergoing developmental epigenetic changes. Despite this, one of the genes near 
gestational age DMRs, RAPGEF2, and TCEANC2 gene containing mercury-associated 
DMR showed the expected inverse relationship of DNA methylation and gene expression. 
Consistent with this idea, RAPGEF2 regulates embryonic haematopoiesis (Satyanarayana 
et al., 2010), and TCEANC2 is expressed in blood, whereas NFIX and MSRB3 play in the 
development of organs such as brain, tooth, skeletal muscle and bone (Campbell et al., 




expression by methylation patterns of the latter two genes may not be detectable in cord 
blood, or these DMRs may regulate the enhancer function of distal genes or focally 
modify the high-order chromatin structure and thus not manifest a change in cord blood 
expression of NFIX or MSRB3. These results are quite encouraging for epigenetic 
epidemiology in general, since they indicate that DNA methylation differences may be 
widespread, and methylation profiles in blood may be a useful indicator of developmental 
change even in tissues that do not utilize the differentially methylated genes in normal 
developmental processes.  
Overall, the results obtained here by genome-wide DNA methylation analysis are 
encouraging for the field of epigenetic epidemiology, since they indicate that DNA 
methylation differences are detectable with this strategy. Specifically, this work identifies 
epigenetic changes associated with gestational age at birth and mercury exposure. The 
underlying reason for this correlation cannot be determined in this cross-sectional study 
or the replication study, but there are several implications of these findings for the 
epidemiology of PTB and mercury exposure. 
First, regions of the genome that are still undergoing DNA methylation variation 
late in gestation may be functionally related to the health consequences of PTB, and our 
findings can inform new epidemiologic research and biological mechanisms towards 
understanding the reasons for negative outcomes in premature babies and lessening these 
negative infant, childhood or even adult health consequences related to gestational age at 
birth.  
Secondly, it is possible that these results reflect involvement of DNA methylation 




to inflammation (Leitich and Kiss, 2007), preeclampsia (Moldenhauer et al., 2003) and 
stress (Smith, 2007)) and risk factors (African American race, bacterial vaginosis, 
cigarette smoking and low maternal pregnancy body mass index (Behrman, 2007; 
Kramer et al., 2011)) associated with PTB, which could be associated with epigenetic 
changes themselves, although this explanation is less consistent with the function of the 
particular genes identified in our study. In addition, the use of assisted reproductive 
technology and nutritional deficiencies have been identified as possible risk factors for 
PTB (Dunlop et al., 2011; Henderson et al., 2012) and also have the potential to alter the 
epigenome (Chmurzynska, 2010; DeBaun et al., 2003). Identification of epigenetic 
changes associated with PTB potentially could be useful for identifying, among the many 
factors associated with PTB, which are most likely to be causal factors, although our 
design did not contain a large number of spontaneous PTBs and thus the relationship 
between methylation and causes of PTB may be best suited for subsequent studies in 
different samples.  
Thirdly, the findings in our study further implicates about the biological effect of 
low level mercury exposure, particularly methyl mercury, in neonates. Although 
historical cases such as Minamata disease or Iraq poison grain syndrome showed negative 
health outcomes due to high level methyl mercury exposure on both adults and 
children(Bakir et al., 1973; Social Scientific Study Group on Minamata Disease, 1999), 
low level methyl mercury exposure in utero is also associated with brain function deficits 
in childhood (Grandjean et al., 1997), and the negative effect of the exposure on 
cognitive development in children is more apparent when adjusting with maternal fish 




Jorgensen et al., 2007; Strain et al., 2008). Our results provide further evidences along 
with these reports by showing that mercury exposure mostly within normal exposure 
range is associated with epigenetic differences in neonates. Also, methylation changes 
associated with mercury exposure is not confounded by n-3 fatty acid levels, which 
serves as one of the indicators for maternal fish consumption, suggesting that the 
methylation differences we observed would be more associated with negative health 
outcomes. Thus, our findings would help understanding more about the potential 
mechanisms of negative health outcomes on neonates by mercury exposure, particularly 
methyl mercury, in utero. 
Further work is required to determine whether the detection of DNA methylation 
in non-primary proxy tissues (in this instance, blood) indeed is a useful indicator of 
developmental change in the primary tissue for expression of affected genes or functional 
changes induced by mercury exposure. However, the work presented here shows that 
DNA methylation changes progressively during late fetal development or changes 
associated with mercury exposure, thus opening the door to studies of the epigenetic 
epidemiology, and possibly helpful by providing reference data which would be part of 
integrating environmental exposure status, birth outcomes, genetics, and epigenetics of 
neonates. Together with other findings, the findings presented in this thesis would help to 
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